Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NASDAQ:GILD

Gilead Sciences Inc. (GILD)

124.08
-1.51 (1.20%)
as of Jun 15, 2026, 8:08:45 pm Market Open.
143 watching
0
DON'T BUY
It is less of a diversified company than big pharma. He is not big on investment in this sector. It is a tough place to be. It would be better at a lower price.
DON'T BUY
Very disappointing. The update from the new CEO wasn't particularly exciting. Their HIV prep drugs is doing well. However with the Hepatitis C drug coming off patent, they have lost revenues. Deep value but they need to execute. They like the high yield with great premiums on the options. He would rather own another diversified biotech or a basket.
HOLD
A drug company that was the poster boy for high prices for drugs including hep-C creating some bad sentiment. The company has a good pipeline on HIV drugs. It trades at less than 9 times earnings. The worst is behind them. Yield 4%
DON'T BUY

It has been a bit of a value trap for years. They were effective in the cure for HEP-C. For them it has been a declining revenue steam. They made an acquisition that did not work out. Revenues have dropped 40% over the last 5 years. He would stay clear of it.

BUY
It's been painful as it consolidates for the past 18 months. They have a hepatitis franchise, an expensive drug, that came off patent. Gilead failed to reinvest those profits, too. Their HIV franichise is doing very well. They acquired some companies, which look promising. The CEO is doing a good job. They are trading 9.5x fowarding earnings. Great dividend yield and balance sheet.
PAST TOP PICK
(A Top Pick Jun 27/18, Down 5%) An analyst just issued a sell report on them -- calling for a 10% downturn. It trades about 8.5 times earnings. They were victims of their success in hepatitis medicine as it cured too many people, he says. It pays a 4% yield.
BUY
Value trap for so long for so many. Cure for Hep C had generated huge cash flow. HIV franchise is leading the pack. Yesterday's numbers are fantastic. Likes that they've diversified their assets. New CEO gave realistic guidance. Likes it at these levels.
N/A
The pharmaceuticals and the health technology are not his skill set. The balance sheet is OK for a pharmaceutical. The analyst community seems to like it. (Analysts’ price target is $80.70)
HOLD
He's owned this for four years, but it's struggled in the past two as they've transitioned from their hepatitis C drug era (limited growth). But they just announced great results on a new HIV drug. It's a value trap though looking cheap at 9x earnings. Pays a 3.8% dividend. They still generate lots of cash flow. He'd stick with it. At least you get that yield. Also, they just got a new CEO, so they're in transition.
DON'T BUY
Stay away. It's a broken chart. Simple as that. Also, there will be a wall of sellers on the way up, if and when it does go up.
HOLD
He still likes it here and especially at these valuations. The new CEO will be good. They have announced a couple of new joint ventures and it is trading at less than 10 times earnings. Their HEP-C advantage has been declining, but they have growth in their HIV franchise.
WATCH
A frustrating stock. They have expensive drugs, such as for hepatitis C. They failed to build out their franchise and not making acquisitions, and have only been doing that in the past few years. Their HIV franchise is doing quite well, though. They acquired Kite Pharma which could be a game-changer later. It's trading at 10x earnings. Upcoming catalysts are a liver study in Q1/Q2 could be positive. Maybe. But is GILD a value trap or opportunity? Buy it as its chart improves.
TOP PICK
Value play. It's been hammered, trading at around 10X future PE, cheap. The market is valuing their HCV business to basically zero, and that's the side of the business that's been hurt with the generics coming out and pushing the prices lower. Their HIV business has been doing pretty well. New CEO coming in, they have $32B in cash and waiting to see how this cash will be spent. Yield 3.3%. (Analysts’ price target is $86.95)
WAIT
Has had a pullback over the last 3 years. Their return on capital has gone down. They have had tough competition and some products going off patent. He would wait to see improved results before he decided on a position.
DON'T BUY
This is a US biotechnology company. They are big on treatments for HIV and hepatitis. It trades at a cheap valuation. There is competition from other big pharma and generics and biologics. It is reasonably cheap but depends on finding new markets for their drugs.
Showing 31 to 45 of 264 entries